Clinical and Economic Outcomes of New Oral Anticoagulants in Orthopaedics

1. Cushman M. (2007). Epidemiology and Risk Factors for Venous Thrombosis. Semin Hematol. 44(2), 62-9. DOI: 10.1053/j.seminhematol.2007.02.004.10.1053/j.seminhematol.2007.02.004202080617433897Open DOISearch in Google Scholar

2. Tagalakis V, Patenaude V, Kahn SR, Suissa S. (2013). Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort. Am J Med. 126(9), 832.e13-21. DOI: 10.1016/j.amjmed.2013.02.024.10.1016/j.amjmed.2013.02.02423830539Open DOISearch in Google Scholar

3. Goldhaber SZ. (2012). Venous thromboembolism: Epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 25(3), 235-42. DOI: 10.1016/j.beha.2012.06.007.10.1016/j.beha.2012.06.00722959540Open DOISearch in Google Scholar

4. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. (2007). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 98(4), 756-64. DOI: 10.1160/TH07-03-0212.10.1160/TH07-03-0212Open DOISearch in Google Scholar

5. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. (2012). Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl), e278S-325S. DOI: 10.1378/chest.11-2404.10.1378/chest.11-2404327806322315265Open DOISearch in Google Scholar

6. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. (2008). Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl), 381S-453S. DOI: 10.1378/chest.08-0656.10.1378/chest.08-065618574271Search in Google Scholar

7. Falck-Ytter Y, Warwick D, Dahl OE, Fisher WD; International Surgical Thrombosis Forum. (2008). Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br. 90(2), 127-32. DOI: 10.1302/0301-620X.90B2.20106.10.1302/0301-620X.90B2.2010618256075Open DOISearch in Google Scholar

8. Bass AR. (2015). Using new oral anticoagulants in patients undergoing major orthopedic surgery. Curr Rheumatol Rep. 17(4), 25. DOI: 10.1007/s11926-015-0498-z.10.1007/s11926-015-0498-z25854486Search in Google Scholar

9. Eriksson BI, Quinlan DJ, Weitz JI. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 48(1), 1-22. DOI: 10.2165/0003088-200948010-00001.10.2165/0003088-200948010-0000119071881Open DOISearch in Google Scholar

10. Wong PC, Crain EJ, Pinto DJ, Watson CA. (2007). Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in Prevention and Treatment of Thrombosis in Rabbit Models of Arteriovenous-Shunt and Venous Thrombosis at Doses That Preserve Hemostasis. Blood 110, 933.10.1182/blood.V110.11.933.933Search in Google Scholar

11. Wong PC, Pinto DJ, Zhang D. (2011). Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 31(4), 478-92. DOI: 10.1007/s11239-011-0551-3.10.1007/s11239-011-0551-3Open DOISearch in Google Scholar

12. Imberti D, Gallerani M, Manfredini R. (2012). Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolysis. 34(2), 208-13. DOI: 10.1007/s11239-012-0716-8.10.1007/s11239-012-0716-8Open DOISearch in Google Scholar

13. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. (2009). Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 361(6), 594–604. DOI: 10.1056/NEJMoa0810773.10.1056/NEJMoa0810773Open DOISearch in Google Scholar

14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P and the ADVANCE-2 investigators. (2010). Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807-15. DOI: 10.1016/S0140-6736(09)62125-5.10.1016/S0140-6736(09)62125-5Open DOISearch in Google Scholar

15. Lassen MR, Gallus A, Raskob G, Pineo G, Chen D, Ramirez LM. (2010). Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 363(26), 2487–98. DOI: 10.1056/NEJMoa1006885.10.1056/NEJMoa100688521175312Open DOISearch in Google Scholar

16. Huang J, Cao Y, Liao C, Wu L, Gao F. (2011). Apixaban versus enoxaparin in patients with total knee arthroplasty: a meta-analysis of randomized trials. Thromb Haemost. 105(2), 245-53. DOI: 10.1160/TH10-08-0552.10.1160/TH10-08-055220941455Open DOISearch in Google Scholar

17. Werth S, Halbritter K, Beyer-Westendorf J. (2012). Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Ther Clin Risk Manag. 8, 139–47. DOI: 10.2147/TCRM.S24238.10.2147/TCRM.S24238333346022547932Search in Google Scholar

18. Eriksson BI, Dahl OE, Buller HR, et al. (2005). A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Thromb Haemost 3(1), 103–11. DOI: 10.1111/j.1538-7836.2004.01100.x.10.1111/j.1538-7836.2004.01100.x15634273Open DOISearch in Google Scholar

19. Eriksson BI, Dahl OE, Huo MH, et al. (2011). Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 105(4), 721–9. DOI: 10.1160/TH10-10-0679.10.1160/TH10-10-067921225098Open DOISearch in Google Scholar

20. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. (2009). Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 101(1), 77–85. DOI: 10.1160/TH08-07-0493.10.1160/TH08-07-0493Open DOISearch in Google Scholar

21. Wurnig C, Clemens A, Rauscher H, Kleine E, Feuring M, Windhager R, Grohs J. (2015). Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery. Thromb J. 13, 37. DOI: 10.1186/s12959-015-0066-9.10.1186/s12959-015-0066-9Open DOISearch in Google Scholar

22. Schulman S, Majeed A. (2012). The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. Semin Thromb Hemost. 38(1), 7-15. DOI: 10.1055/s-0031-1300946.10.1055/s-0031-1300946Open DOISearch in Google Scholar

23. Mismetti P, Laporte S. (2008). Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim. 27 (Suppl 27), S16–S21. DOI: 10.1016/S0750-7658(08)75142-6.10.1016/S0750-7658(08)75142-6Open DOISearch in Google Scholar

24. Steffel J, Luscher TF. (2009). Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown). 10(8), 616-23. DOI: 10.2459/JCM.0b013e32832edac0.10.2459/JCM.0b013e32832edac0Search in Google Scholar

25. Eriksson BI, Borris LC, Friedman RJ, et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358(26), 2765–75. DOI: 10.1056/NEJMoa0800374.10.1056/NEJMoa0800374Open DOISearch in Google Scholar

26. Kakkar AK, Brenner B, Dahl OE, et al. (2008). Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31–9. DOI: 10.1016/S0140-6736(08)60880-6.10.1016/S0140-6736(08)60880-6Open DOISearch in Google Scholar

27. Lassen MR, Ageno W, Borris LC, et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 358(26), 2776–86. DOI: 10.1056/NEJMoa076016.10.1056/NEJMoa076016Open DOISearch in Google Scholar

28. Turpie AG, Lassen MR, Davidson BL, et al. (2009). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 373(9676), 1673–80. DOI: 10.1016/S0140-6736(09)60734-0.10.1016/S0140-6736(09)60734-0Open DOISearch in Google Scholar

29. Turpie AG, Haas S, Kreutz R, et al. (2014). A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 111(1), 94-102. DOI: 10.1160/TH13-08-0666.10.1160/TH13-08-066624154549Open DOISearch in Google Scholar

30. Anderson DR, Dunbar MJ, Bohm ER, et al. (2013). Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 158(11), 800–6. DOi: 10.7326/0003-4819-158-11-201306040-00004.10.7326/0003-4819-158-11-201306040-0000423732713Open DOISearch in Google Scholar

31. Nutescu EA. (2013). Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. Expert Opin Pharmacother. 14(4), 525–34. DOI: 10.1517/14656566.2013.774374.10.1517/14656566.2013.77437423438423Open DOISearch in Google Scholar

32. Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. (2013). A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for postsurgical venous thromboembolism prevention. Postgrad Med. 125(4), 141-53. DOI: 10.3810/pgm.2013.07.2686.10.3810/pgm.2013.07.268623933902Open DOISearch in Google Scholar

33. Arrayas IG, Fernandez CS, Cerezo J G, Nicolás L B, Salas-Cansado M, Rubio-Terres C. (2012). Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement. Rev Esp Salud Publica. 86(6), 601-12. DOi: 10.4321/S1135-57272012000600006.10.4321/S1135-5727201200060000623325135Open DOISearch in Google Scholar

34. NICE. (2012). Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance [TA245].Search in Google Scholar

35. NICE. (2008). Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance [TA157].Search in Google Scholar

36. Zindel S, Stock S, Müller D, Stollenwerk B. (2012). A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res. 12, 192. DOI: 10.1186/1472-6963-12-192.10.1186/1472-6963-12-192355168022776616Open DOISearch in Google Scholar

37. Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. (2011). Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 11(5), 601-15. DOI: 10.1586/erp.11.65.10.1586/erp.11.6521958104Open DOISearch in Google Scholar

38. Pravilnik o Listi lekova koji se propisuju i izdaju na teret sredstava obaveznog zdravstvenog osiguranja. Službeni glasnik RS 65/15; 71/15; 104/15, 24/16, 57/16, 61/16.Search in Google Scholar

39. WHO Collaborating Centre for Drug Statistics Methodology. (2016). Guidelines for ATC classification and DDD assignment 2016. Oslo: World Health Organization.Search in Google Scholar

40. Republički zavod za statistiku. Baza podataka. Retrieved Jun 01, 2016. from: http://webrzs.stat.gov.rs/WebSite/public/ReportView.aspx.Search in Google Scholar